A total of four EGFR TKIs (gefitinib, erlotinib, lapatinib, and afatinib) are currently in clinical use, with gefitinib, erlotinib, and afatinib being employed to treat lung cancer, while lapatinib (which inhibits both EGFR and Her2) is used for breast cancer. Here, EGFR is linked to breast cancer.